European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

EBiSC2 – A sustainable European Bank for induced pluripotent Stem Cells

Descripción del proyecto

DE EN ES FR IT PL

El banco ético de células madre de Europa está ampliando exponencialmente su utilidad y alcance

La investigación con células madre es muy prometedora, aunque históricamente ha planteado problemas éticos sobre los aspectos morales del uso de embriones humanos. A lo largo del último decenio, un descubrimiento sorprendente ha evolucionado para trasformar la faz de la investigación con células madre. Las células madre pluripotentes inducidas (iPSC, por sus siglas en inglés) son células somáticas humanas adultas, normalmente células cutáneas y sanguíneas, que se reprograman genéticamente a un estado de células madre embrionarias. Actualmente, Europa posee un banco de iPSC y el proyecto EBiSC2 está trabajando en el marco que impulsará su diversidad, normalización y capacidad de favorecer la investigación académica y comercial con un plan de negocio sostenible.

Objetivo

EBiSC2 builds on the achievements of the European Bank for iPSCs (EBiSC1) in centralising existing capacities across Europe in a unique banking and distribution infrastructure for research use in response to the increasing demand for human induced pluripotent stem cells (iPSC). Significant progress towards this aim has been made by EBiSC1; further resources, however, are required to ensure self-sustainability. Key partners of EBiSC1 who have delivered major assets of the current bank, join efforts to establish EBiSC2 as self-sustainable, central bank.
Based on a gap analysis of the EBiSC1 endeavours towards sustainability, and focussing on user demand, scientific excellence and productivity, EBiSC2 will deploy a business strategy for a sustainable, non-for-profit bank providing access to disease-relevant and quality-controlled iPSCs, along with comprehensive data and freedom to operate for academic and commercial use. To meet evolving requirements from industry and academia, the cell catalogue will be constantly enriched through on-demand generation of new iPSC lines, including gene-edited lines and isogenic controls, iPSC-derived and progenitor cells. EBiSC2 will distribute cell lines and develop a range of additional cell services (incl. screening panels of disease-relevant iPSC and control lines in ready-to-use-formats) to extend its offer, while reducing operational costs through state-of-the-art upscaling and automation enabling bulk production of standardised high-quality cells. Proof-of-concept studies performed jointly by academia and industry will demonstrate the reliability and robustness of the lines for disease modelling and screening and enrich the EBiSC2 catalogue with extensive data.
To bundle resources, EBiSC2 focuses on collaboration with iPSC programmes and aims to serve as central hub for EU-funded projects to bank their iPSC lines, and thus, enable long-term access by the research community to the results of European investments.

Ámbito científico

Palabras clave

Programa(s)

Tema(s)

Convocatoria de propuestas

H2020-JTI-IMI2-2017-13-two-stage

Consulte otros proyectos de esta convocatoria

Régimen de financiación

RIA - Research and Innovation action

Coordinador

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Aportación neta de la UEn
€ 2 841 583,93
Dirección
HANSASTRASSE 27C
80686 Munchen
Alemania

Ver en el mapa
Región
Bayern Oberbayern München, Kreisfreie Stadt
Tipo de actividad
Research Organisations
Enlaces
Coste total
€ 3 432 708,93

Participantes (18)

Compartir esta página

Descargar

Última actualización: 1 Febrero 2024

Mi folleto

Permalink: https://cordis.europa.eu/project/id/821362/es

European Union, 2024